Recently, reactivation of MAPK pathway, mediated by NRAS amplification or MET transcriptional regulation, has been linked to the emergence of resistance to FGFR inhibitors in FGFR1-amplified lung cancer cell models (38). This evidence concerns the gene NRAS and lung carcinoma.